Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies — AtTRIBut  

Cancer Clinical Trial

Official title: Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry

Status Recruiting

Clinical Trial Summary

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

Clinical Trial Description

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

It is within this context that this registry was set up to gather information from physicians and patients treated with molecular agents and radiation therapy. The information being collected include diagnosis, doses received, type of targeted therapy, side effects, etc. Through this registry, we wish to determine whether there are more Grade 3 or above side effects than what is reported in the literature for these treatment modalities, when given alone or in combination. Participating patients will also describe their perceived side effects and quality of life. ;

Related Conditions & MeSH terms

• Cancer
• Radiotherapy Side Effect

• NCT number: NCT04115267
• Study type: Observational [Patient Registry]
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Contact: Mom Phat, RN
• Phone: 1-514-8908000
• Email: mom.phat.chum@ssss.gouv.qc.ca
• Status: Recruiting
• Start date: September 13, 2019
• Completion date: September 30, 2025